Psyence Biomedical Ltd is a life science biotechnology company that focuses on developing natural psilocybin products for the treatment of psychological trauma and related mental health conditions in palliative care settings. The company conducts its research and development through its operating subsidiary Biomed II and aims to create pharmaceutical grade psilocybin therapies that can be used alongside psychotherapy to address disorders such as adjustment disorder, alcohol use disorder, anxiety and depression. Psyence Biomedical Ltd seeks to establish a global standard for consistency and efficacy in nature‑based psychedelic drug development.

Psyence Biomedical Ltd currently does not generate commercial revenue from product sales as it remains in the development stage. The company’s financial activities consist primarily of research and development expenditures, licensing related payments and costs associated with clinical trial execution. It has entered into research and supply agreements with partners such as Filament and PsyLabs, under which it may receive milestone payments or obtain raw material for future trials, but no product sales revenue has been reported to date.

Psyence Biomedical Ltd operates in an emerging industry where no pharmaceutical agent has received regulatory approval for the treatment of adjustment disorder within palliative care or any other indication. This absence of approved therapies creates a potential first mover opportunity for the company’s psilocybin‑assisted psychotherapy approach. The company believes its clinical asset PEX010 holds a first mover advantage in the palliative care and cancer‑related adjustment disorder markets upon approval. Competitive advantage is derived from an exclusive license for PEX010 in the United Kingdom for research and development purposes, access to a portfolio of patents covering extraction, purification, stabilization and delivery methods held by Filament, and the potential to leverage the entourage effect of naturally sourced psilocybin. Additionally, the prior breakthrough therapy designation for psilocybin in severe depressive disorder may facilitate expedited regulatory pathways for the company’s future product candidates.

The company’s customer base consists primarily of patients receiving palliative care who suffer from adjustment disorder due to incurable cancer, as well as healthcare providers and clinics that administer psychedelic assisted psychotherapy. Psyence Biomedical Ltd collaborates with Filament for the supply of PEX010, engages Southern Star Research as a contract research organization to conduct its Phase IIb Study in Australia, and works with PsyLabs to secure a supply of pharmaceutical grade psilocybin for future investigations in alcohol use disorder and substance use disorder. Patients also access the investigational product through Health Canada’s Special Access Program, which provides PEX010 for end of life distress and major depressive disorder under supervised medical use.